0001477932-13-004233.txt : 20130917 0001477932-13-004233.hdr.sgml : 20130917 20130917170938 ACCESSION NUMBER: 0001477932-13-004233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130917 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130917 DATE AS OF CHANGE: 20130917 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 131101942 BUSINESS ADDRESS: STREET 1: 120 WALL STREET STREET 2: SUITE 2401 CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: (646) 961-4459 MAIL ADDRESS: STREET 1: 120 WALL STREET STREET 2: SUITE 2401 CITY: NEW YORK STATE: NY ZIP: 10005 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 8-K 1 uhp_8k.htm FORM 8-K uhp_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report: September 17, 2013
(Date of earliest event reported: September 16, 2013)

UNITED HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)

Nevada
  
814-00717
  
84-1517723
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

c/o Morse & Morse, PLLC
1400 Old Country Road, Suite 302
Westbury, NY 11590
 (Address of principal executive offices, zip code)

(516) 487-1452
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
 
 
 
 
 
Item 7.01.  Regulation FD Disclosure

On September 16, 2013, the Company issued a press release, a copy of which is appended hereto.

Item 9.01.  Financial Statements and Exhibits.
 
Exhibit   Description
     
99.1
   Press release dated September 16, 2013.  (Filed herewith.)
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
UNITED HEALTH PRODUCTS, INC.
  
       
Dated: September 17, 2013
By:
/s/ Dr. Phillip Forman
  
   
Dr. Phillip Forman
  
   
Chief Executive Officer
  
 
 
3
 EX-99.1 2 uhp_ex991.htm PRESS RELEASE uhp_ex991.htm
Exhibit 99.1
 
News  
 

United Health Products Receives Notice of Allowance for Patent Application for HemoStypeTM Gauze Product – Anticipates First Orders from Dental and Medical Markets

Westbury, NY - September 16, 2013 - United Health Products, Inc. (OTCQB: UEEC) announced that it has received formal notification of allowance of its patent application from the U.S. Patent Office for its hemostatic gauze product, HemoStyp™, and that the patent will issue shortly. The Company is also pursuing additional applications and filings for its HemoStyp product line.
 
HemoStyp is an all-natural product comprised of regenerated oxidized cellulose gauze which is specifically formulated to aid in the process of hemostasis (clotting) when positioned on a cut or wound. Unlike the other products in the wound care market, HemoStyp contains no potentially harmful chemicals or animal byproducts and is hypoallergenic. Once it has completed its task, it is easily removed by dissolving it in water or saline solution. This method of removal neither disturbs the clotted surface nor encourages re-bleeding.
 
Dr. Phillip Forman, CEO of United Health Products, stated that, "Now that the Company has obtained full patent rights for HemoStyp, we look forward to entering the next phase of sales and marketing with our patented product."
 
The Company expects its first orders from the dental and medical markets as it is now pursuing multiple markets for HemoStyp including the medical, sports, dental, military, and veterinary sectors, each of which represents a multimillion dollar market.
 
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets a patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStypTM, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
 
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
 
Company Contact: IR Contact:
Dr. Philip Forman, CEO Terri MacInnis, Dir of IR
United Health Products, Inc. Bibicoff + MacInnis, Inc.
646-808-3104
terri@bibimac.com 818-379-8500

GRAPHIC 3 img001.jpg begin 644 img001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,# M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_ MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``W`6<#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]#/\`@I)_ MP6)A_P""8G[:WPS\.^-;#[=\+_B)H\SWE[;1YO=`NH;A4^T`#_6PE9%WI]X; M_M6?"+2E?+Z=X6NKAU[KYMW@?F(JYG_`(-M/^"OES^S'\6+7X'?$#5P M/AOXOG;^Q+N[FVQ^'-08$[-S<+!.>".BR$'C/:48I775*^^_A_VLJ>,E0JNT>C[:=?(_H#^*_QBT#X)^&8M8\2 MZC'INGS7D%@DKC.Z::01H,?4Y)[`$G@5T\3[USG<#T([U^/'_!27]M>3]K+X MEIINC2RQ>"O#4CQZ>.5^WS=&NF'IC(0'HN3U/'Z6_L)?%J7XU?LG>"=>NI/, MOI-/2UNV)RS30_NV)]R5R?W$T37$:AWC#@NJG."1 MU`.#@^QJ7=QG-?,YZT`%%&@`HH)P,FB@`HHHH`****`"BC.,9[T4`%%%%`!103CD]J"<4`%%`.1 MGK10`4444`?S)?\`!TO\1I?&O_!6#6M(=B8_!_A[2]-0>GF0_:S_`.E-?G/% MTGU-N8L>R&ORETK37UG5;>TC4N]S*L:KTW9.,5_L%X+9IE;\+\%B%;V- M.@U43[P3]I?U:D_1GPF,PE:OF+PU.+E.M['ZD>$_%27GPUT;6M M3GBMOM6G03SR2-M4,T8)_$G)QUYKW+X/HJC+,QX` M!-?\[>74ZF`SC$XO+I6E5E-126BC*5TEY[:G]T?1M_9^9)P-3GQ=X@XCVN(E M!RE1B^6C2C=2:G+1S:MKJH[JSW?[3?\`!`./Q1\4/A1\0_BYXTU?4->\1^/= M=%LU]=ON:2&U3:%4=$17D37UY^R'^SGI_[)W[-GA'X?Z MB_M3_P#!9KX%_P#!/;QAX;\%_%;7]6T36=5\*KX@M'CTV2ZBNXU(B$*&/+-. M[@[4"\XR2*\I_P"#HVZ1?^"26O6[.!/>^+/#T%NG\4TG]IPMM4=SM5CCT!K@ M?CQ\&_#_`,6/^#DS]FV#Q/I-OJB>&?A'>ZS:6]U&)(XKR*5TCD96!!*&0L,] M&"D<@5WGR)Z_\*_^#B/X%^./BIX=\)^*-!^+GPEN/%URMEHFH^//",VCZ;J4 M['Y(UG+,JEN,%]J\CD9K9_X*`-X37_@IM^QV-;\=>+/#OB`ZOK?]B:'IUDTV MG^(W^Q+YBW<@=1$(U^925?))&!UJA_P\0WOB[]N_\`X)6:MJ,[W.H:I8ZA M=W,S\M++)H5N[L3ZEB3^-`'D/[?7_!:3P38_\%GOV?=7M-.^,EMX>^%C>)M( M\2:?'X=NHWU>!P"#WK].?VC/^"H?P=_9-_9J\)_%+X@Z M_>>'=&\=6=M=:#IDUA*VM:H\\22I;QV:@RF8+(@=<80G#$5\P_\`!1!BO_!P M'^PP,G_D%>+?_2:&OGW]K7QS\5?$'_!RAX@O?"7P8TWX]ZI\(?AW8S>%]!U/ MQ);Z+#H`NFC:;4HO/5EEDWR-'D#*[U.05&`#Z:T'_@Y*^#-AXITVT^(7P]^/ M7P;T/69D@LO$OC?P6^GZ-*SMM7=,DDAC!QG+J`!R<#FON[7?B?X<\,?#NY\7 MZCKNE6?A6SL3J*_4^'3*T]O;O<0,4V!RR@9R!;) MT`Q0!]YW_P#P$W[5FVC`_?<#&*`/UK<'@]Z_.C_@E=XIU76O^"R'_``4&L+W4 MM1O;'2]:\++96T]R\D-H&L;HL(T)VH"0"=H&<#/2OT7;M]:_%+X(?LC?$_\` M:H_X+3?MV?\`"N/V@/%OP,_L/6_#HU`:)IT%Y_;7FV,WEF3S?N^5Y;XQU\TY MZ4`?5/\`P)=3\(_\`!)+Q1?:5J-_I=['XCT!5N+.=[>8!M3@!`92"`0<5 M]4_M%?MA?#O]A[]G(?$+XI^*+/PSX:T^UA5KB?=)-&]5T:TMK6[ M9]0A1'9X_F!1B'`'!*\UV_\`P5N\6^/_`!?_`,%JOV8/"FA?"RU^,]IX.\$7 M/BW1/!NHZ_#I-AJ.H@R*UX7E5D=X%BC8(02?+STS0!]#K_P![IP(O&6M^`Y8=$*,0%E+I(TBH2PP3'SFOO7X?_`!7\-?%7X;:9 MXQ\.:[IFM>%=9LEU&RU6TN%DM+BW9=PE60'&W'4GI@YQ@U\&^*?VR?VV/'/A MF_T36_V#/#>J:/JD#VMY9W/Q3TZ6&YB<;61E,6""#C!KX'\>?#[]H#_@GK_P M;X_'SP1XNT:/X>Z%X@^(5MI^A6]GK]OK#^'M"U.YC^UVWGPN0$4@QG.TGSW. M!NH`_0OQY_P&32F ML55IX;U'P\$N'!4%2&'()%>U?L@_L^^#/V6OV:_!O@;P#IUCIGA?0]+@BM%M M$"KI>([.U01K+/''+$EV5'`>505)'WC"2>220"_^Q7^U5#^S=^V3_P`%'/&_ MBZ7Q;KOAKP1XQT1ET_38)M3NH4DMW3;;VX/=F4D+C@9/2O,?^"'?_!63PGXV M_;L_:"\+7=G\5;R?XN_$Q[WPP;O0[F2UTBW^S,?*NF8D69^4_(?:O?/^"/W_ M`"E-_P""A'_8]:-_Z134_P#X(=,3^UU^WCD_\UB?_P!)Z`/F+_@D[_P6F^'O M[(?PK^)G@CQ;)\3?B7\1[_XK^);NW\.^%M&N=?U.UL!<1HDK\A8XMP8*-V># M@8K]'?V"/^"LOPB_X*):OX@T/P9=>(=%\9^$PKZQX5\3:7)I6LV$;$`2-"^= MR9(!92<%AG&1GY8_X-A_A'X=T'X/_'[QG;:7;)XH\0_%_7["_P!2*`SS6]O, MIBAW8R$4R.VW.,L3UK7_`&L;&T^&G_!RY^RIK.E6L5KJ/Q%\#>)M$UN:)0CW MT%K;O^+?B; MI>A^"_#?A>^TRV\-^)IM,CCDGT^W$FY5#`@XSP!R2>'+NW1' M2XMIF`(3,B`@`<;\[OE(^I-?_P""[GP"T#]IV\^#7V_Q7?\`Q)L?%R^#9-%L MM$EN)A<$QAKHE256T4R@&5B.C8!P:Y/]D+_@CIXM\,?M=Z7\??VB_C3J7QV^ M*'ABTEL?#$8TN/2M&\,QR@AW@MT)S*59ANX^\20Q"D<9_P`$7/!>DM_P4D_; M^\1G3;1]='Q+AL%OC$#<+;B"1_*5CRJEB20.IQG.!0![]^W3_P`%C/A#^P9X M_P!.\#ZR/%GCGXEZM"+FU\&>"]);5];:$])7B#*L:G!(WNI(&0".:Y_]DW_@ MN7\'_P!J#XXVGPPU32/B+\(/B1J@9M+\._$/03HMUJX7.1;-O>*1N#A0^XX. M`<5X7_P;;^%]+^*^F_M"?'+Q"D>H?%[QI\3]7TK7+RY(EO-+M;9T$%BI/,<: MJWW1C(5.RKCM_P#@YK^$'A7Q;_P2H\:>-M6>+2O%GPOGLO$'A/7(P$O--U!+ MJ)$6*3[R^9OV8!QDJ>J@@`^M_P!KW]M#X:?L(?!J\\>_%/Q39>%O#EHWE+), M&DFNY2"5A@B0%Y9#@X5`3@$\`$U\B:%_P'?C%9QZEHWA M+X&0_$#2M&OQFTO?$,S1B9VA;Y7DC&7`(.#`#T!K]5_BG\*?#GQO^'.L^#_% MNC6&O^&O$%H]CJ&G7D(E@N(74JRE3['@CD$`C!H`_-'_`((8?M=Z5\+/V!?V MK_BUXOU_5?$'A'P=\7_%>L&]AF;4'.FQ6]I*OV?+?,FPY55('S<=:_27X$_& MG1?VBO@QX6\>>'&NFT'QAID&KZ>;F+R9C!,@=-Z9.UL$9':OQ1_X)^>`M*^& M?_!NW^W]X8\/7#7VA>'?%OC;3=-G!+^=;0Z=:)&^>_R*.>^,U^J/_!))UD_X M)@?`$J0X/@32>0<@_P"BI0!U7PC_`&X/`_QL_:E^)OP?T235F\8_"6*QFUY9 M[3R[95O$9X?*DS^\X4YX&*\'_:7_`."\WP:^`?QIU7X<>'=$^)GQI\=>'B1K M6D_#GP\VM-HI!(*W$I=(E<%2"H*^3-/\`BCKGP>_X*&?\%4?%GA4R M-XC\-_#_`$B]T]X&S);SQZ7=,L@ZX*'#X_V:^I_^#=?X(>$_A-_P28^%.L>' M;:WDU7Q]I@\1^(=4&'NM5U"=V,KS2'+.R$>6`3P$QUS0!Z/^P;_P5Q^#W_!0 MW7-9\.^$+W7O#_COPY&)=5\(>*=,?2='_$.C:WI:^&;J.?4;E_,CCDAM<_Z1&K# M)<#Y0`>*_4WXO?L'_";XF_M;_#[XU:Q9/I7Q1\$&6VTG5K#4&L)M1B=2K6UP MJD"YCVLP",#@.1T-?+/[8#$?\')'[(WOX#\4?^B7H`]:_;)_X+:_"#]BL^"] M-U73_'WC'QKX^TF+7=*\(>%=";4-=%E(H8330%D$0^\,,P;*/@':<>G?L!_\ M%%?AE_P4G^#D_C3X::E?36VG7C:;JNG:E:FTU'1[I0"8;B(D[6P0002I'0\' M'R#^W?\`LB?'OX*?\%05_:U_9VTCP;\5]0_X1%?"OBGP)JU^MGJ'D(WF"2SF M8[4=@J?*2#E3\KAR!ZE_P1A_:P^#O[6FF_%G6_`OPIF^#'Q0M_$0B^)OAJ[M MQ%>QZG^\VRR,`HD#'S@&V(VY7!4<9`/N`'/-%`Z"B@#YW_X*?_L!:%_P4C_9 M)\0?#K5I(K'56Q?Z!J;)N;2]0C4^5)ZE&R4<#JCMWQ7\R.A_L2>/_P!GOX]: MSX9\<>%]4TOQ+X=N6LELOL[RFZD[30D#]Y&RD,K+D$,#7]>U%?%^L.@^:,'+EBY+ MX7)\LKJ+UMI=];'\Y7[//_!(CX^_M'ZI;+9>!K_PWI=P06U7Q"IL+:)#_$%8 M>8^/15YK]A/^"R;A+`Y=+VL$Y3[OIZ+9'ZCXE_2&XJXRH/`8F<:&&>].G= M*7^*3;E+TNEY#`,#G)-?!?\`P4E_X)H_%7X@?M<>"OVE_P!FOQCX>\)?&3PC MIK:!J>G>((Y#I'BW2RY<6\[1@L"I8]1@_*049%)^]Z*^H/PD_+KQ)_P3]_:X M_P""G_QH^'D_[5=[\*_`/PA^&^MP^(F\'>"+FYNY_$U]`283<2RDA8ADCALA M6;"Y;%O`5]X4N=.=IO[1EN)YC(LB` M)Y?E@<'+@Y[&OJNB@#P#_@J+^RAKO[-C^\*':1WXK[>HH`^3OVI?V"/%'QT_P""F_[.?QNT MS6-!M/#OP_AD$FHZ9>Q,9(]060_>G\UG=B`V*^JJ*`/S2\&_#S_@IO\``#PE M#\.](U_]G'XFZ98Q"STSQYXB-_::K!`%"1R7-O'\LDJ@`D@/N/5FZE__``3- M_P""*WQ._8N_X*,^)_CQX]^*^F_$[4/'OA-K3Q%>2Q2P7LNL27*2.88]GEI9 MI%&B(-^[Y?NJ,`?I510`CD\5\F?L4_L"^*/V9_\`@H!^U/\`%O6-8T"_T+X[ M:AHEYHUG9-,;NP6RMIXI!<;T5`6,JE=C-P#G'`KZTHH`^6?^"QG["_B;_@HQ M^PQK?PM\):MH>B:WJ6K:9J$5WJ[2K:HEK>13N#Y2.VXJA`PN,]2.M4/^"C?_ M``3*?]M/PSX"\2>$?%TWPV^-WPBF^V^#?%]K`)EM9&15EMKB,_ZVVE"@,IZ= M<$%E;ZUHH`_-/Q+X3_X*@?&GPO(-1O M)2-0UB^F8/)?E^=DPE5'3&0GEQCG;S]744`?F)\*?V=_^"B?[!G@Z'X9?#OQ M-\#?C?X`TE/L7AO7?&\E[8ZYH]FNX10W`A.V;RUV@'+G"@9`^58OV._^"*OQ MM^&7_!3KPC^U'\6_C!H/Q#\97.F:I:^*[:"WFMK>Q\Z$16=KIL>S'V>(%]Q< MQGD84G)/Z@44`?*7["W[!_B?]EO]LK]I_P")&M:QH.H:1\OE#X`?L%>*/A+_`,%8OC_\?K_6-!N?#'Q9T/0]+TS3X&F-_9R6-M'% M(TP9!&%9D)7:S'!&0*^L**`$49`)ZU\K_L!?L*>)_P!DK]I3]ICQIKNKZ%J. MG?&SQHGB72(+!I3-8P+$R&.XWHH#Y(^X6'O7U310!^=/QL_X)F_'3]E#]K7Q M?\;OV//%G@ZR/Q*E%]XV^&_C!9ET+6;T')O;:2+YH)WRQ;[N2S'<0=HQ+_\` MX)S_`+3O_!3CXC>%;K]L+7OASX8^$G@_48]9C^&O@-[B=/$-[%_JFO[F4DF% M3D^6K,#DC"\-7Z8T4`?'W_!3S_@EU/\`MJ77@7Q[\.?&#_"OXY_"2=KCP?XG MA@\VW2-O]997,0^_;N.,8.W+?*RLRGQ7Q/\`##_@I9^TKX6D^'/BGQ#^SY\* M-`OT^Q:SXX\*F^O-:NK8C;*UI!(=D4KKG!.S;G@CK7Z5T4`?!?\`P21_X(ZW M?[!G[!WQ7^`_Q`US2?&.@_$/Q'K%PL]BTN^32KVRM[0)/YB+BX*1.6V@J"PP M37D?P"_98_X*'_\`!/'X46_P9^%VJ?L_?$WX=Z#YEIX5\1>*I+VSU71K-G.`,XX'ZH44`?G?_`,$G/^"0_P`2_P!BS]HGX_>-_C#\0?#/ MQ8F^.5I8?VA<16LD,UQ<*L_VM)H601K`3-L0*QRBC(7[M$/&TEQ#:M2+H0BKE25YW?>#?+W MW_!(#_@F[XV_8LG^+'Q#^+GBG1O%?QC^.FNIKOB27186BTNP"!_+MX`P!.#+ M(2V`,;0`=NYOM:B@`'04444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` 7%%%%`!1110`4444`%%%%`!1110!__]D_ ` end